KCM
BHVN

KRS Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

KRS Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,355
Closed -$204K – 110
2022
Q3 		$204K Sell
1,355
-2,460
-64% -$365K 0.28% 93
2022
Q2 		$555K Sell
3,815
-2,003
-34% -$256K 0.79% 36
2022
Q1 		$689K Sell
5,818
-35
-0.6% -$4.37K 0.75% 36
2021
Q4 		$806K Buy
+5,853
New +$744K 0.69% 34

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

KRS Capital Management's BHVN Position: Q4 2022 in Review

KRS Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,355 shares — an estimated $204K sold.

KRS Capital Management first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $806K in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • KRS Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • KRS Capital Management sold 1,355 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $204K.
  • KRS Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • KRS Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $806K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on KRS Capital Management's 13F filing for Q4 2022, filed 19 Jan 2023.